Navigation Links
Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Date:5/12/2008

, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: one to prevent traveler's diarrhea and three targeting influenza and pandemic flu.
Iomai is listed on the NASDAQ Global Market under the symbol "IOMI".

For more information on Iomai, please visit: http://www.Iomai.com

Additional Information and Where to Find It:

In connection with the proposed transaction, Iomai Corporation will be filing a proxy statement for its stockholders and other documents regarding the proposed transaction with the Securities and Exchange Commission (SEC). BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, IOMAI STOCKHOLDERS AND INVESTORS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND IOMAI. Investors and stockholders may obtain copies of the proxy statement and other relevant documents filed with the SEC by Iomai free of charge at the SEC's web site at http://www.sec.gov. In addition, investors and stockholders may obtain copies of the proxy statement and other relevant documents filed with the SEC by Iomai (when they are available) by going to Iomai's Investor Relations page on its corporate website at http://www.iomai.com.

Iomai and its directors, executive officers and other members of management may be deemed to be participants
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. U.S. Preventive Medicine Acquires Specialty Disease Management
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
8. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...Data Published in ,The Lancet, and Presented at ES...- Results from a new international,study, the GISS...d dose of,omega-3 acid ethyl esters reduced all ca...scular reasons in patients with chronic heart,fail...nline version of ,The,Lancet, and were presented a...
(Date:9/4/2008)... Updated Survival Data for Ipilimumab to be Pre...tCall/ -- Medarex, Inc.,(Nasdaq: MEDX ) announced...,an investigational anti-CTLA-4 antibody, in mela...ons at the 33rd Congress of the European Society,f...-16, 2008 in Stockholm.,Many of the following abst...
(Date:9/3/2008)...ays: Wrong Question Asked. Wrong Children Studied....PRNewswire-USNewswire/ -- A Centers for Disease,Co...aims there is no link,between the MMR vaccine and ... this study does nothing to dispel the growing pub...aises several questions concerning design,and meth...
(Date:9/3/2008)...SELS, Belgium and GENEVA, Sept. 3 /- ...lestone in CHO based monoclonal antibody,productio...over 31 grams,per liter. This record level was acc...logies: (1) a high-performance stable Selexis CHO,... leading scientists at,Selexis SA using their prop...
Breaking Medicine Technology:New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3CDC Misses Target With Flawed MMR/Autism Study 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3How fast youll age is written in the bones TAU research finds 16411 1How fast youll age is written in the bones TAU research finds 16411 2Boston College biologists build a better mouse model for cancer research 16409 1Boston College biologists build a better mouse model for cancer research 16409 2UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam 16407 1UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam 16407 2UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam 16407 3UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam 16407 4An Eye Opening Look at Insomnia 16405 1An Eye Opening Look at Insomnia 16405 2
... 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc....nical trial of GVAX immunotherapy,for pancreatic c...ney Kimmel Cancer Center. The trial enrolled 60 pa...d GVAX after surgical,resection of their tumor and...n overall survival for these patients was previous...
...000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, 20...d today at the American Society of,Clinical Oncolo...e,clinical activity of cilengitide in patients wit...rly aggressive form of brain tumor.,Cilengitide is...he,tumor and its vasculature. , Fifty-two patients...
Other Medicine Technology:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 2Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 3Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 4Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 5Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...es that not only fight cocaine and methamphetamine...ms. The study was conducted by a team of researc...at Baylor College of Medicine (BCM). As part of t...xamined the effect of the vaccines on subjects adm...
...le of detecting and measuring all known forms of h...r physicians in managing patient therapy. Abbott ...nced today that Abbott has received CE marking for...eaction) test for monitoring hepatitis B (HBV) vir...
...ial Programme for Research and Training in Tropica...trengthening and expanding research to prevent and...rategy builds on the programmes 30-year record of ...egies and enhancing research capacity in countries...
...Advisory Board for its transplantation programs. I...on of its United States (U.S.) clinical developme... and Larry Chodoff LifeCycle Pharma A/S OMX:LCP) t...Scientific Advisory Board (SAB) of experts in the ...
Other Medicine News:Health News:Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe 2Health News:Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe 3Health News:LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation 2
...atory system for pH and temperature measurements. ... when used with a temperature probe (ATC) or a 3-i...int calibration with Auto-Find automatic buffer re...0.01 and 12.45) and Auto-Read for locking onto sta...
...atory system for pH and temperature measurements. ... when used with a temperature probe (ATC) or a 3-i...int calibration with Auto-Find automatic buffer re...0.01 and 12.45) and Auto-Read for locking onto sta...
...atory system for pH and temperature measurements. ... when used with a temperature probe (ATC) or a 3-i...int calibration with Auto-Find automatic buffer re...0.01 and 12.45) and Auto-Read for locking onto sta...
...tional high-end microplate reader with outstanding... modes., Fluorescence Intensity - FRET , Fluores... HTRF, AlphaScreen , Luminescence , , , PHERAst...der with fastest read times. The ultimate solution...
Medicine Products: